Breaking News

Catalent, BrainStorm Enter ALS Drug Manufacturing Pact

Catalent will undertake the transfer of the manufacturing process to, and provide future cGMP clinical supply of NurOwn from its Houston facility.

By: Contract Pharma

Contract Pharma Staff

Catalent and BrainStorm Cell Therapeutics Inc., a developer of cell therapies for neurodegenerative diseases, entered an agreement for the manufacture of NurOwn, BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS). NurOwn induces mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons and neuroprotection. The therapy has received Fast Track status from the U.S. F...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters